4/15/1993 • Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers.

4/15/1993 • Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers.

De Bellis MD, Geracioti TD Jr, Altemus M, Kling MA
Clinical Neuroendocrinology Branch, National Institute of Mental Health,National Institute of Health, Bethesda, Maryland.

Biol Psychiatry 1993 Apr 15-May 1; 33 (8-9); 636-41

CSF 5-HIAA and MHPG decreased significantly… following fluoxetine treatment.
Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7687151&dopt=Abstract

De Bellis MD, Geracioti TD Jr, Altemus M, Kling MA
Clinical Neuroendocrinology Branch, National Institute of Mental Health,National Institute of Health, Bethesda, Maryland.

Biol Psychiatry 1993 Apr 15-May 1; 33 (8-9); 636-41

CSF 5-HIAA and MHPG decreased significantly… following fluoxetine treatment.

Cerebrospinal fluid (CSF) levels of the monoamine metabolites 5-hydroxyindoleacetic acid (5-HIAA), 3-methoxy-4-hydroxyphenylglycol (MHPG), and homovanillic acid (HVA) were measured in three groups: 46 healthy volunteers; 9 medication-free patients with DSM III-R major depressive disorder, recurrent; and these same 9 patients following at least 4 weeks of fluoxetine treatment at 20 mg/day. CSF monoamine metabolite levels in medication-free patients did not differ from healthy volunteers; however, CSF 5-HIAA and MHPG decreased significantly from 95.9 +/- 24.6 (all values +/- SD) to 64.2 +/- 26.1 pmol/ml and from 46.7 +/- 14.2 to 42.6 +/- 11.6 pmol/ml, respectively, following fluoxetine treatment. Fluoxetine also significantly decreased mean Hamilton Depression Rating Scale scores from 23.2 +/- 6.5 to 17.4 +/- 5.0 and significantly increased the CSF HVA/5-HIAA ratio.
PMID: 7687151, UI: 93320172

702 total views, no views today

5/17/1975 • Fenfluramine in man: hypophagia associated with diminished serotonin turnover.

5/17/1975 • Fenfluramine in man: hypophagia associated with diminished serotonin turnover.

Shoulson I, Chase TN

Clin Pharmacol Ther 1975 May 17(5) 616-21

The results support the contention that the effect of fenfluramine on human dietary intake may be mediated by alterations in serotonergic rather than dopaminergic mechanisms.
Fenfluramine in man: hypophagia associated with diminished serotonin turnover.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1092516&dopt=Abstract

Shoulson I, Chase TN

Clin Pharmacol Ther 1975 May 17(5) 616-21

The results support the contention that the effect of fenfluramine on human dietary intake may be mediated by alterations in serotonergic rather than dopaminergic mechanisms.

A double-blind trial of orally administered fenfluramine was conducted in 7 non-obese adults with various neurological disorders. Caloric intake and body weight fell significantly after 8 days of treatment although there was no definite change in appetite ratings. Average central turnover of serotonin, as estimated by the cerebrospinal fluid (CSF) accumulation of 5-hydroxyindoleacetic acid (5-HIAA) during probenecid loading, decreased by 66%. No significant change in homovanillic acid, the major dopamine product, was apparent.
Publication Types: Clinical trial Controlled clinical trial PMID: 1092516, UI: 75148833

823 total views, 1 views today